MARKET OUTLOOK The Crohn’s disease (CD) therapy market will continue to evolve over the next decade. The well-established tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., Janssen/Merck’s…
MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…
In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the…
The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12 and -23…
Despite the availability of multiple oral atypical antipsychotics in the United States, long-acting depot formulations of atypical antipsychotics offer a compelling advantage because of their less…
The hepatitis C virus (HCV) therapy market has been marked by tremendous growth, and the treatment landscape has undergone a rapid evolution with the launch of novel direct-acting antivirals (DAAs…
Abstract: Owing to the large diagnosed prevalent population, relatively high rates of drug treatment across patients of all disease severities, and high rates of polypharmacy—particularly among…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
Osteoarthritis (OA) is a painful, degenerative condition that is characterized by the gradual development of joint pain, as well as joint stiffness and limitation of movement in the joints. Of…
The schizophrenia therapy market is mature and very crowded given the presence of numerous atypical and typical antipsychotic agents, including the continued genericization of key oral therapies,…
The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the…
Obesity is a significant public health concern in the major pharmaceutical markets under study and is growing into an epidemic. Despite the prevalence of the disease, few drugs are available to…
Market Outlook Atypical antipsychotics—the cornerstone of schizophrenia treatment—are available as oral and long-acting depot formulations in the United States. Many of the oral atypical…